新闻发布 - Huya Bioscience International

HUYA Bioscience International Presents Positive Data on HBI-8000 at Society for Immunotherapy of Cancer Meeting

November 11, 2020/in 2020 /by hwkA5jb3

Study confirms tolerability and significant anti-tumor activity of HBI-8000 in combination with nivolumab in checkpoint naive melanoma patients

San Diego, CA, USA – 9 November 2020 – HUYA Bioscience International (HUYABIO^TM), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the presentation of results from an ongoing Phase II study evaluating the efficacy and safety of HBI-8000 in combination with nivolumab in patients with advanced metastatic melanoma.

HUYA Bioscience International Submits HBI-8000 Monotherapy for Adult T-cell Leukemia/Lymphoma for Regulatory Approval in Japan

October 7, 2020/in 2020 /by hwkA5jb3

San Diego, CA, USA – October 6, 2020 HUYA Bioscience International (HUYABIO^TM), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the submission of a regulatory application to the Japanese Pharmaceuticals and Medical Devices Agency for HBI-8000 monotherapy for relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATL).

HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 Monotherapy Adult T-cell Leukemia-Lymphoma ATL in Japan

September 30, 2020/in 2020 /by hwkA5jb3

San Diego, CA, USA – September 28, 2020 HUYA Bioscience International (HUYABIO^TM), the leader in accelerating global development of China’s pharmaceutical innovations, announced today the Ministry of Health, Labour and Welfare (MHLW) granted HBI-8000 orphan drug designation (ODD) in Japan as monotherapy for relapsed or refractory Adult T-cell Leukemia-Lymphoma or (ATL).

HUYA Bioscience International Licenses the Novel SHP2 Inhibitor HBI-2376 for Development in Oncology

August 5, 2020/in 2020 /by hwkA5jb3

SAN DIEGO, CA, USA – August 4, 2020 HUYA Bioscience International (HUYABIO^TM), the leader in accelerating global development of China’s pharmaceutical innovations, announced today it has exclusively licensed worldwide rights, outside of China, to the SHP2 inhibitor, HBI-2376, from Suzhou GenHouse.

SHP2 is an important component of RAS signaling pathway leading to activation of ERK/MAPK pathways in a variety of cancer cells.

HUYA Bioscience International Announces the Successful Completion of Phase 1 Trial of HBI-3000

March 10, 2020/in 2020 /by hwkA5jb3

Phase 2 trial will test the unique multi-channel ion blocker in acute atrial fibrillation

San Diego, CA, USA – February 28, 2020 HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, has presented the results of a Phase I study of HBI-3000, a novel drug for cardioversion of atrial fibrillation (AF).

HUYA Bioscience International Appoints Meiji Seika Pharma as Exclusive Distributor For HBI-8000 in Japan and Other Asian Countries

January 9, 2020/in 2007 /by hwkA5jb3

Meiji Seika Pharma to Commercialize HUYABIO’s Product in Lymphoma

San Diego, CA, USA – January 8, 2020 – HUYA Bioscience International CEO & Executive Chair, Dr. Mireille Gillings announced the appointment of Meiji Seika Pharma (Meiji) as an exclusive distributor for its lymphoma product, HBI-8000, in Japan. Meiji also acquired exclusive rights for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.

HUYA Bioscience International expanded oncology pipeline includes combination with checkpoint inhibitor for solid tumors

June 8, 2018/in 2018 /by hwkA5jb3

San Diego, CA, USA – June 4, 2018 – HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it is at a key stage in the company’s development of HBI-8000, HUYA’s lead novel epigenetic drug with important immunomodulatory properties. HUYA is conducting a Phase 2 trial of HBI-8000 in the US, investigating efficacy and safety in combination with nivolumab for the treatment of solid tumors.

HUYA Bioscience International Establishes Strategic Partnership with Suzhou BioTOP

July 10, 2017/in 2017 /by hwkA5jb3

San Diego, CA, USA – July 10, 2017 – HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced a strategic collaboration agreement with Suzhou BioTOP Technical Service Co., Ltd. (referred to as BioTOP). The collaboration will focus on promoting the development of biomedical innovations from companies and research organizations in Suzhou BioBay that help to meet the increasing demand to fill global pharmaceutical pipelines.

HUYA Bioscience International and CAS Innovation and Investment Company Establish Strategic Collaboration

January 25, 2017/in 2017 /by huyausa

San Diego, CA, USA – January 18, 2017 –HUYA Bioscience International (HUYA), the leader in accelerating the global development of China’s pharmaceutical innovations, announced today a strategic collaboration agreement with the Chinese Academy of Sciences Innovation and Investment Company (referred to as CAS Innovation). The collaboration will focus on developing and commercializing biomedical innovations discovered by leading scientists at CAS to meet the medical needs of patients around the world.

HUYA Bioscience International Sponsors 12th Annual Scrip Awards ‘Best New Drug’ Category

December 14, 2016/in 2016 /by hwkA5jb3

San Diego, CA, USA – December 14, 2016 – For the second straight year, HUYA Bioscience International (HUYA) was a proud sponsor of the Best New Drug category at the Annual Scrip Awards.